Literature DB >> 26542584

Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery.

Rebecca A Marmor1, Kaitlyn J Kelly1, Andrew M Lowy1, Joel M Baumgartner2.   

Abstract

BACKGROUND: Completeness of cytoreduction is a significant predictor of long-term outcome after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Imaging has limited sensitivity to identify peritoneal metastases and therefore predict whether complete cytoreduction is possible. We reviewed our experience using laparoscopy to determine candidates for complete cytoreduction and HIPEC.
METHODS: This single-center, retrospective study examined patients from 2007 to 2014 who underwent laparoscopy to determine complete cytoreduction (CC-0/1)/HIPEC candidacy. Preoperative, intraoperative, and postoperative data were collected.
RESULTS: A total of 145 laparoscopies were performed on 141 patients, 72 (51.1 %) of whom were female, with a median age of 53 years (range 20-79). The primary site was appendiceal in 67 (47.5 %) patients, colorectal in 43 (30.5 %), mesothelioma in 17 (12.1 %), unknown in 9 (6.4 %), small bowel in 3 (2.1 %), gastric in 1, and ovarian in 1 (0.7 % each). Overall, 115 (81.6 %) patients had prior abdominal surgery, 111 (76.6 %) had evidence of disease on imaging, and 117 (80.7 %) underwent prior chemotherapy, with a median of 5.9 weeks between the last treatment and laparoscopy (0.9-498.9 weeks). Four (2.8 %) intraoperative complications were observed (one liver laceration, two enterotomies, and one air embolus), and nine (6.2 %) postoperative complications [four (2.8 %) Clavien grade (CG) I, three (2.8 %) CG II, one (0.7 %) CG III (return to operating room) and one (0.7 %) CG IV (transient ischemic attack)]. Forty-eight patients deemed candidates by laparoscopy underwent CRS/HIPEC (positive predictive value 82.8 %).
CONCLUSION: Diagnostic laparoscopy is a safe, feasible, and accurate staging tool in patients with suspected peritoneal metastases being considered for CRS.

Entities:  

Mesh:

Year:  2015        PMID: 26542584     DOI: 10.1245/s10434-015-4958-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

Review 1.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 2.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

3.  Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.

Authors:  David N Hanna; Muhammad O Ghani; Andrew Hermina; Alexander Mina; Christina E Bailey; Kamran Idrees; Deepa Magge
Journal:  Am Surg       Date:  2021-11-03       Impact factor: 0.688

4.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin.

Authors:  Fabio Carboni; Orietta Federici; Settimio Zazza; Francesco Corona; Fanny Massimi; Isabella Sperduti; Mario Valle
Journal:  Langenbecks Arch Surg       Date:  2021-10-23       Impact factor: 3.445

5.  Selection Criteria for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Special Emphasis on Laparoscopy as an Efficient Tool.

Authors:  Miklos Acs; Aydin Dadras; Sebastian Blaj; Hubert Leebmann; Pompiliu Piso
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

6.  Accuracy of radiologic- laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome.

Authors:  Shimaa Abdalla Ahmed; Hisham Abou-Taleb; Noha Ali; Dalia M Badary
Journal:  Br J Radiol       Date:  2019-05-24       Impact factor: 3.039

7.  Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis.

Authors:  Whitney Guerrero; Gitonga Munene; Paxton V Dickson; Zachary E Stiles; Johnathan Mays; Andrew M Davidoff; Evan S Glazer; David Shibata; Jeremiah L Deneve
Journal:  J Gastrointest Oncol       Date:  2018-08

8.  Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin.

Authors:  Jan Marie de Gooyer; Fortuné M K Elekonawo; Andreas J A Bremers; Otto C Boerman; Erik H J G Aarntzen; Philip R de Reuver; Iris D Nagtegaal; Mark Rijpkema; Johannes H W de Wilt
Journal:  Nat Commun       Date:  2022-05-12       Impact factor: 17.694

9.  Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy.

Authors:  Whitney L Guerrero; Gitonga Munene; Paxton V Dickson; Dina Darby; Andrew M Davidoff; Michael G Martin; Evan S Glazer; David Shibata; Jeremiah L Deneve
Journal:  J Gastrointest Oncol       Date:  2018-04

10.  The role of single-incision laparoscopic peritoneal exploration in the management of patients with peritoneal metastases.

Authors:  Haythem Najah; Brice Malgras; Anthony Dohan; Caroline Gronnier; Clarisse Eveno; Marc Pocard
Journal:  Surg Endosc       Date:  2019-07-18       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.